SEOM clinical guidelines on cardiovascular toxicity (2018)

• Juan A. Virizuela ^[1] ; A. M. García ^[2] ; R. de las Peñas ^[7] ; A. Santaballa ^[8] ; R. Andrés ^[3] ; C. Beato ^[1] ; S. de la Cruz ^[4] ; J. Gavilá ^[5] ; S. González-Santiago ^[9] ; T. L. Fernández ^[6]
  1. [1] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  2. [2] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  3. [3] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  4. [4] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  5. [5] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  6. [6] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  7. [7] Hospital Provincial de Castellón
  8. [8] Hospital Universitari i Politècnic la Fe
  9. [9] Complejo Hospitalario Universitario de Cáceres

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 1 (January 2019), 2019, págs. 94-105
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor’s prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM’s ongoing commitment to progressing and improving supportive care for cancer patients.